Last reviewed · How we verify
ChAd63 ME-TRAP
At a glance
| Generic name | ChAd63 ME-TRAP |
|---|---|
| Sponsor | University of Oxford |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults (PHASE2)
- Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults (PHASE1, PHASE2)
- A Study to Assess the Safety and Immunogenicity of a Candidate Malaria Vaccine Using Novel Routes of Administration (PHASE1)
- An Efficacy Study of IV Boosting With ChAd63/MVA ME-TRAP (PHASE1, PHASE2)
- A Safety and Efficacy Study of R21 +/- ChAd63/MVA ME-TRAP (PHASE1, PHASE2)
- A Phase 1/2b Study of an Investigational Malaria Vaccination Strategy in 5-17 Month Old Infants and Children in Burkina Faso (PHASE1, PHASE2)
- A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S (PHASE1, PHASE2)
- A Phase I Study to Assess the Safety and Immunogenicity of ChAd63 ME-TRAP - MVA ME-TRAP Heterologous Prime-boost Vaccination Co-administered With EPI Vaccines in Gambian Infants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ChAd63 ME-TRAP CI brief — competitive landscape report
- ChAd63 ME-TRAP updates RSS · CI watch RSS
- University of Oxford portfolio CI